Normally, αIIbβ3 on circulating platelets exists in a "resting" form. On platelet activation, αIIbβ3 is activated and its binding of ligand forms adhesive bonds that transmit "outside-in" signals, which induce a series of intracellular events, such as protein phosphorylation, elevation of intracellular Ca
I
ntegrins are cell surface transmembrane receptors that mediate adhesion to the extracellular matrix.
1,2 Integrin function is modulated by bidirectional transmembrane signaling, inside-out and outside-in, which is mediated through the interactions between integrin cytoplasmic tails and intracellular, regulatory proteins. The major integrin of platelets, αIIbβ3, plays an essential role in adhesion, spreading, and aggregation in vitro and in thrombosis and hemostasis in vivo. [3] [4] [5] Antagonists of αIIbβ3 are potent antithrombotic drugs, and new inhibitors targeting αIIbβ3 are in preclinical testing or large patient trials to treat acute coronary syndromes.
for novel integrin-binding proteins using receptor pull-down and mass spectrometric analysis to gain more insights into αIIbβ3 regulation. Unexpectedly, VPS33B was found to be associated with β-integrins. VPS33, a homologue of yeast Vps33p, is known to be involved in multiple endomembrane trafficking steps. 16 It is a core component of 2 sorting complexes, the class C core vacuole/endosome tethering and the homotypic fusion and vacuole protein sorting. 17, 18 In humans, mutations in either VPS33B or its binding partner, VPS16B, are associated with a recessive disorder called arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome. [19] [20] [21] [22] This is a multisystem disorder in which most patients die within 1 year of birth. Many develop severe hemorrhages, which is most likely because of a deficiency in α granules, reminiscent of that seen in grey platelet syndrome. 23 These data show that at least 1 role for VPS16B/VPS33B is in α granule biogenesis. In our studies, we showed that the interaction between VPS33B and αIIbβ3 was important for outside-in signaling and a number of platelet functions. Using a platelet factor 4-promoter-driven excision system, we maintained normal α granule biogenesis and were able to focus on the acute effects of VPS33B on platelet functions. Platelets deficient in VPS33B had defective spreading and fibrinogen uptake and were unable to mediate normal hemostasis. Our results are some of the first to establish vesicle targeting complexes as an important novel class of modifiers of integrin function.
Methods

Generation and Characterization of VPS33B -/-Mice
All of the animal experiments were approved by the institutional animal care and use committee of the University of Kentucky. The protocol used to generate platelet-specific VPS33B conditional knockout mice is described in the online-only Data Supplement Methods section.
Platelet Aggregation and Secretion
Mouse platelet preparation, platelet aggregation, and ATP release were prepared as described previously. 24 The detailed procedures are available in the online-only Data Supplement Methods section.
Immunoblotting Analysis of Myosin Light Chain Phosphorylation
Myosin light chain (MLC) phosphorylation was detected by Western blot. The detailed procedures are available in the online-only Data Supplement Methods section.
Fibrinogen Binding Assay
Fibrinogen binding to cells was analyzed by flow cytometry. The detailed procedures are available in the online-only Data Supplement Methods section.
Detection of PF4 in Platelets
The total amount of PF4 in platelet lysates was measured using the antimouse ELISA kit from R&D Systems (Minneapolis, MN) following the manufacturer's instruction.
Integrin Expression
Integrin β3 or αIIbβ3 expression was analyzed by flow cytometry. The detailed procedures are available in the online-only Data Supplement Methods section.
Platelet Spreading on Fibrinogen and PlateletMediated Clot Retraction
Platelet spreading and clot retraction were performed as described previously. 25 The detailed procedures are available in the online-only Data Supplement Methods section.
Measurement of Mouse Platelet Serotonin
Serotonin was measured as described previously. 25 The detailed procedures are available in the online-only Data Supplement Methods section.
Coimmunoprecipitation and Binding Assays
The protocol used to detect VPS33B and integrin interaction by coimmunoprecipitation is described in the online-only Data Supplement Methods section.
Glutathione S-Transferase Bead Pull-Down Analysis
Platelet lysates, lysates from Chinese hamster ovary (CHO) cells expressing FLAG-tagged VPS33B, or purified FLAG-VPS33B were incubated with glutathione beads bound to glutathione S-transferase (GST), GST-αIIbCD, GST-β1CD, GST-β3CD, or various GST-β3CD truncated mutants at 4°C overnight. Bead-bound proteins were analyzed by immunoblotting. The detailed procedures are available in the online-only Data Supplement Methods section.
RhoA and Rac1 Activity Assay
The protocols used to measure RhoA and Rac1 activity are available in the online-only Data Supplement Methods section.
Detection of Endocytosis of Fibrinogen in Platelets
Purified human fibrinogen (Sigma-Aldrich, St Louis, MO) was biotinylated by an EZ-link sulfo-NHS-Biotinylation kit (Fisher Scientific, Pittsburgh, PA) according to the manufacturer's instruction. VPS33B
+/+ and VPS33B -/-mice (male, 8-9 weeks old) were injected retro-orbitally with 5.0 mg per mouse of biotinylated fibrinogen. Blood was collected from the animals 24 hours after injection of the biotinylated fibrinogen. Platelets were harvested, washed, and solubilized in SDS sample buffer. Biotinylated fibrinogen in platelet lysates was analyzed by immunoblotting with a horseradish peroxidase-conjugated avidin.
Bleeding Time and In Vivo Thrombosis
Tail bleeding time assay and in vivo thrombosis model were performed as described previously. 24 The detailed procedures are available in the online-only Data Supplement Methods section.
Statistical Analysis
Data were analyzed using unpaired Student t test. The nonparametric Mann-Whitney test was used for comparison of tail bleeding times and occlusion times to thrombus formation between 2 groups. Values of P<0.05 were considered significant.
Results
VPS33B Binds to the Cytoplasmic Domain of β Integrins
To identify novel binding partners of integrin αIIbβ3, agarose beads conjugated with GST-β3 integrin cytoplasmic domain fusion protein (GST-β3CD) or GST-αIIb integrin cytoplasmic domain fusion protein (GST-αIIbCD) were incubated with human platelet lysates. Proteins bound to GST-β3CD or GSTαIIbCD beads were subjected to mass spectrometric analysis. The GST-β3CD beads successfully precipitated known β3 cytoplasmic domain binding proteins, that is, talin 1 and 2, 6, 13 kindlin 2 and 3, 8, 14, 15 Src kinase, 9,10 and integrin-linked protein kinase. 26, 27 The GST-β3CD beads also precipitated several adhesion complex proteins, such as myosin, vinculin, and tubulin. Surprisingly, the GST-β3CD but not the GST-αIIbCD beads specifically bound the vacuolar protein sorting-associated protein 33B (VPS33B), encoded by the VPS33B gene.
To further verify that VPS33B associates with αIIbβ3, we infected CHO cells, stably expressing αIIbβ3 (A5 cells), with an adenovirus containing FLAG epitope-tagged human VPS33B cDNA. Cells were allowed to adhere and spread on fibrinogen and were immunostained with a fluoresceinlabeled anti-FLAG monoclonal antibody and a phycoerythrin-labeled monoclonal antibody against integrin αIIb. As shown in Figure 1A , FLAG-VPS33B exhibited a significant intracellular colocalization with αIIbβ3. To evaluate the physical interaction between VPS33B and αIIbβ3, A5 cells expressing FLAG-tagged VPS33B were solubilized, and anti-FLAG immunoprecipitation was performed. Immunoblotting analysis revealed a specific association of β3 with FLAG-VPS33B. Comparable levels of β3 were seen in the total cell lysates with or without FLAG-VPS33B ( Figure 1B ). Coimmunoprecipitated β3 was detected by immunoblotting with a mouse anti-β3 monoclonal antibody, SZ-21.
28,29
The specific interaction was confirmed by reciprocal immunoprecipitation using a specific β3 antibody ( Figure 1C) . Furthermore, in an in vitro binding assay, we were able to recover VPS33B from the lysates of CHO cells overexpressing VPS33B on GST-β3CD beads ( Figure 1D ). Agarose beads conjugated with GST-β1 integrin cytoplasmic domain (GST-β1CD) fusion protein but not with GST-αIIbCD could also bind VPS33B from the cell lysates. Thus, VPS33B specifically interacts with the cytoplasmic domain of integrin β subunits. The interaction between VPS33B and β subunits of integrin appears to be direct, because we were able to pull down purified FLAG-VPS33B ( Figure IA in the online-only Data Supplement) with GST-β3CD and GST-β1CD proteins ( Figure 1E ).
To map the VPS33B binding site in β3, we generated GST fusion proteins containing various truncations of the β3 cytoplasmic domain ( Figure 1F ). The pull-down assay data showed that the β3 fragment spanning residues 716 to 730 bound efficiently to FLAG-VPS33B ( Figure 1G ). In contrast, the fragments containing either residue 729 to 762 or residue 744 to 762 fragments did not bind. There are 2 talin binding sites in β3, the conserved NPLY sequence and another binding site for talin head domain between residues 722 and 738. 30 This second site appears to overlap with the VPS33B binding site. To determine whether talin binding to β3 affects VPS33B binding, we established a stable CHO cell line expressing the talin head domain. Overexpressing the head domain did not inhibit but appeared to enhance VPS33B binding to β3 ( Figure 1H ). The N-terminal 145 amino acids of VPS33B appeared to be critical for binding for β3 ( Figure 1I ).
Lo et al 23 reported previously that VPS33B is only present in megakaryocytes and not in platelets; however, recent studies by the same group described the successful detection of VPS33B in platelets using a newly generated antibody. 31 Consistently, VPS33B was readily detectable in human platelet lysates ( Figure 1J and 1K) . Moreover, VPS33B could be immunoprecipitated with a specific polyclonal antibody and then detected by immunoblotting with a separate monoclonal antibody ( Figure IB in the online-only Data Supplement). Figure 1J shows that, like overexpressed FLAG-VPS33B, platelet VPS33B bound GST-β3CD and GST-β1CD but not GST alone or GST-αIIbCD. The interaction with platelet VPS33B was also dependent on residues 716 to 730 of β3CD (Figures 1K and IC in the online-only Data Supplement). Finally, using a rabbit polyclonal antibody against VPS33B, we coimmunoprecipitated an endogenous β3 subunit with VPS33B from human platelet lysate ( Figure 1L ), indicating the presence of the complex under physiological conditions. Binding of VPS33B to β3 was reduced when platelets were activated with thrombin ( Figure 1M ). 
VPS33B Is Required for αIIbβ3 Outside-In Signaling in CHO Cells
To investigate the role of VPS33B in integrin activation, we first used a recombinant, CHO cell model of integrin activation. A5 cells were infected with an empty virus or an adenovirus encoding VPS33B cDNA. Two days after infection, >80% of the cells were infected and were positive for VPS33B. Although it did not increase surface expression of αIIbβ3 (Figure 2A) , overexpression of VPS33B markedly potentiated cell spreading on fibrinogen ( Figure 2B ). The surface area of cells expressing VPS33B was increased by >2-fold when compared with empty virus infected cells ( Figure 2C ). Cell spreading on immobilized fibrinogen is a standard assay for αIIbβ3 outside-in signaling. 32, 33 Overexpression of VPS33B did not affect cell spreading on poly-l-lysine ( Figure 2B and 2C), suggesting that overexpression of VPS33B specifically potentiates αIIbβ3-dependent cell spreading. To investigate whether VPS33B plays a role in αIIbβ3 inside-out signaling, we used αβPy cells, a CHO cell line that expresses a talin-dependent, constitutively active, chimeric integrin composed of the extracellular and transmembrane domains of αIIbβ3 and the cytoplasmic tails of α6β1. 34, 35 Both αβPy cells and A5 cells were infected with an empty virus or an adenovirus containing VPS33B cDNA. Fibrinogen binding to either αβPy or A5 cells was not enhanced by overexpression of VPS33B ( Figure 2D ). Thus, we identified VPS33B as a specific modulator of the αIIbβ3 outside-in signaling that does not alter integrin expression.
VPS33B Is Required for αIIbβ3 Outside-In Signaling in Platelets
To investigate the role of VPS33B in integrin activation in platelets, we established a mouse model with megakaryocyte-and platelet-specific deletion of VPS33B. We first generated mice harboring a "floxed" VPS33B allele. In the floxed VPS33B mice (VPS33B fl/fl ), exons 2 and 3 of the VPS33B gene, together with an inserted Neo cassette, were flanked with 3 LoxP sites ( Figure 3A ). Megakaryocyte-and platelet-specific fl/fl /Cre -(VPS33B +/+ ) mice were used as wild-type controls. The abundance of VPS33B in the platelets isolated from the VPS33B +/+ mice was comparable with that from the C57BL/6J mice, indicating that insertion of the Neo cassette and LoxP sites had no effect on VPS33B expression. VPS33B -/-mice appeared to develop normally with normal blood counts and without observable changes in platelet number or size ( Figure IIA and IIB in the online-only Data Supplement). VPS33B -/-and VPS33B +/+ platelets had similar levels of surface integrin β3 ( Figure 3C ) or αIIbβ3 complex ( Figure IIC in the online-only Data Supplement). Platelets lacking VPS33B were defective in spreading on fibrinogen ( Figure 3D and 3E). Spreading of VPS33B knockout platelets on collagen or fibronectin was also partially impaired ( Figure III in the online-only Data Supplement). Clot retraction requires αIIbβ3-dependent outside-in signaling. [36] [37] [38] Although the maximal clot retraction of platelets from the VPS33B +/+ mice occurred within 2 hours after the addition of thrombin (0.4 U/mL; Figure 4A 
VPS33B Contributes to α-Granule Biogenesis
In humans, VPS33B is essential for α-granule biogenesis. The α-granule contents, fibrinogen, von Willebrand factor, and fibronectin, were considerably lower in the VPS33B -/-platelets than those of the VPS33B +/+ platelets ( Figure 4E through 4G). In contrast, the expression level of an α-granule membrane protein P-selectin was nearly identical. PF4 levels were only slightly reduced in VPS33B -/-platelets ( Figure 4H ). Consistently, the number of α granules in VPS33B -/-platelets was similar to that in the VPS33B +/+ platelets. Serotonin and β-hexosaminidase, as markers for dense granules and lysosomes, respectively, were not affected by the loss of VPS33B ( Figure 4I and 4J) .
Integrin outside-in signaling is involved in irreversible aggregation and the second wave of platelet secretion. To determine whether VPS33B is involved in agonist-induced platelet activation, we measured aggregation and ATP release in response to thrombin. Platelets lacking VPS33B showed a marked defect in ATP secretion and aggregation in response to low-concentration thrombin or collagen ( Figure 5A and 5B) compared with control VPS33B fl/fl platelets. Although platelet aggregation was not reduced in the VPS33B-deficient mice when stimulated with high concentrations of agonists, ATP release was still lower in the VPS33B knockout platelets than that of wild-type platelets ( Figure 5A and 5B). The expression levels of several elements of the platelet secretory machinery were not overtly affected by the loss of VPS33B ( Figure 5C and 5D ).
VPS33B Is Required for Platelet Endocytosis
Although some α-granule proteins are endogenously synthesized, others, such as fibrinogen, are derived from plasma by endocytosis. The amounts of fibrinogen and fibronectin were ) and VPS33B -/-mice. Coagulation was induced by adding 0.4 U/mL of thrombin, and clots were allowed to retract at 37°C and photographed. Two-dimensional retraction of clots in A was measured using MetaMorph microscopy automation and image analysis software and expressed as the percentage of retraction (B; mean±SD; n=3; *P<0.001 vs WT). C and D, Thrombin-induced fibrinogen binding to VPS33B reduced in the platelets lacking VPS33B, suggesting that VPS33B might play a role in endocytosis. To ascertain the role of VPS33B in αIIbβ3-dependent endocytosis, VPS33B +/+ and VPS33B -/-mice were intravenously injected with biotinlabeled fibrinogen. After 1 day, the amount of biotin-labeled fibrinogen was dramatically reduced in the platelets isolated from the VPS33B -/-mice as compared with that from the control animals ( Figure 5E and 5F).
VPS33B Regulates αIIbβ3 Outside-In Signaling Through a RhoA and Rac1 Pathway
Previous studies have highlighted the importance of the RhoA-ROCK-MLC pathway in α IIb β 3 outside-in signaling leading to clot retraction. 39 Indeed, we observed that MLC phosphorylation and RhoA activation elicited by immobilized fibrinogen were markedly reduced in VPS33B -/-platelets ( Figure 6A  and 6B) . Consistently, overexpression of VPS33B in A5 cells increased immobilized fibrinogen-elicited MLC phosphorylation and RhoA activation ( Figure 6C and 6D) . Consequently, overexpression of VPS33B in A5 cells dramatically potentiated F-actin formation ( Figure VA in the online-only Data Supplement) after cell adhesion to fibrinogen. Although the RhoA-ROCK-MLC pathway is critical for cell retraction and clot retraction, cell spreading is known to depend on the activation of Rac1 and Cdc42 but not RhoA. 38 We found that potentiation of cell spreading by overexpression of VPS33B 
VPS33B Plays an Important Role in Hemostasis and Thrombosis
To investigate whether platelet VPS33B exerts a role in hemostasis, tail-bleeding time tests were performed in 7-to 8-week-old isoflourance-anesthetized littermates generated from mating of VPS33B fl/fl /Cre male mice with VPS33B fl/fl female mice as breeders. Genotyping of the offspring was subsequently determined by polymerase chain reaction analysis. Tail bleeding times were significantly prolonged in the VPS33B knockout mice versus that of wild-type littermates ( Figure 7A ). To evaluate the role of platelet VPS33B in thrombosis in vivo, we compared thrombus formation between megakaryocyte-specific VPS33B-deficient mice and wild-type littermates using the FeCl 3 -injured carotid artery thrombosis model. The median of the time to formation of stable thrombi in the plateletspecific VPS33B-deficient mice was prolonged compared with wild-type littermates ( Figure 7B ). Together, these results suggest that platelet VPS33B plays a role in hemostasis and thrombosis in vivo.
Discussion
Here we identify a new integrin β subunit-binding protein, VPS33B, and show that it is essential for αIIbβ3 outside-in signaling. We further show, distinct from Kindlin-3 and talin, that VPS33B binds to the proximal domain of the integrin β3 subunit. We demonstrate that VPS33B regulates integrin outside-in signaling by promoting RhoA and Rac1 activation, leading to clot retraction and cell spreading, respectively. In addition, our data indicate that VPS33B plays an important -/-mice were added to polystyrene dishes coated with 50 μg/mL of fibrinogen and incubated at 37°C for 15 or 30 minutes and solubilized. RhoA activity was determined as described in Methods in the online-only Data Supplement. Data represent mean±SD of 3 independent experiments, *P<0.01 vs WT at the same time point. C, A5 cells infected with a null virus or an adenovirus-containing FLAG-tagged VPS33B were added to polystyrene dishes coated with 50 μg/mL of fibrinogen (Fg) or buffer and incubated at 37°C for 30, 60, or 90 minutes. Adherent cells were solubilized and phosphorylation of MLCs was analyzed by Western blot analysis. D, A5 cells infected with a null virus or an adenovirus-containing FLAG-tagged VPS33B were added to polystyrene dishes coated with 50 μg/mL of fibrinogen (Fg) or buffer and incubated at 37°C for 30, 60, or 90 minutes. RhoA activity was determined as described in Methods in the onlineonly Data Supplement. E and F, A5 cells infected with a null virus or an adenovirus-containing VPS33B cDNA were pretreated with vehicle or NSC23766 (100 μmol/L) and then added to fibrinogencoated slides. Cells were stained with rhodamine-phalloidin and photographed using a fluorescence microscope. Cell area was normalized to cells infected with a null virus spreading on fibrinogen (mean±SEM; n=147-167; *P<0.0001). G, Washed platelets from VPS33B +/+ (WT) and VPS33B -/-mice were added to polystyrene dishes coated with 50 μg/mL of fibrinogen (Fg) or buffer and incubated at 37°C. Rac1 activity was determined as described in Methods in the online-only Data Supplement. Data represent mean±SD of 3 independent experiments, *P<0.01 vs WT at the same time point. . VPS33B mice have prolonged tail-bleeding times and impaired thrombus formation. A, Mouse tail bleeding times were determined using methods described in the online-only Data Supplement Methods section. Note that although the variances of bleeding times were broad in both wild-type mice (n=17) and VPS33B-deficient mice (n=16), the difference between groups is statistically significant (P<0.02). B, FeCl 3 -induced carotid artery injury was performed and time to occlusive thrombus formation recorded as described in the online-only Data Supplement Methods section. The bars represent the median occlusion time (539 seconds for VPS33B 16 Mutations in the VPS33B gene are associated with ARC syndrome. 19, 20 A deficiency in α-granules is often observed in ARC syndrome patients, 23 indicating that VPS33B is important for human platelet α-granule biogenesis. However, although some α-granule contents, that is, fibrinogen and von Willebrand factor, were considerably lower in VPS33B -/-platelets, the expression of α-granule membrane protein P-selectin was unaffected. The number of morphologically identifiable α-granules in VPS33B -/-platelets was similar to wild-type platelets. These results suggest that it is not essential to have VPS33B present for the entire process of platelet biogenesis, at least in mice.
Our data demonstrate that VPS33B binds directly to β3 and plays an important role in αIIbβ3 outside-in signaling. This role does not involve granule secretion, because in recombinant CHO cells that are not generally thought to undergo regulated exocytosis, overexpression of VPS33B potentiated αIIbβ3-dependent cell spreading. Shen et al 4 reported recently that the EEE motif of β3 integrins (residue 731-733) is required for Gα 13 binding and αIIbβ3 outsidein signaling. We show that the proximal domain of the integrin β3 subunit, residues 716 to 730, is critical for binding to VPS33B. Interestingly, unlike Gα 13 , which promotes cell spreading through c-Src-dependent RhoA inhibition and negatively regulates clot retraction, VPS33B is required for both cell spreading and clot retraction, which is independent of Src signaling (data not shown). Our data suggest that VPS33B regulates cell spreading and clot retraction likely through Rac1 and RhoA, respectively. Integrin outside-in signaling plays an important role for irreversible platelet aggregation and secretion. The findings that platelet aggregation becomes reversible in response to low-dose agonists and that ATP release is diminished in VPS33B-deficient platelets support a role for VPS33B in integrin outside-in signaling. Consistent with the in vitro findings, VPS33B is important for in vivo thrombosis and hemostasis.
Platelet α-granules are crucial not only for thrombosis and hemostasis, but also for inflammation, atherosclerosis, antimicrobial host defense, wound healing, angiogenesis, and malignancy. Aside from its well-recognized roles in platelet aggregation and adhesion, αIIbβ3 also acts as a receptor that mediates endocytosis of fibrinogen, [40] [41] [42] as well as fibronectin. 43 However, the molecular mechanism underlying the αIIbβ3-mediated endocytosis and subsequent incorporation into α granules has remained unidentified. VPS33 is part of the Class C core with VPS11, 16, and 18, which form the class C core vacuole/endosome tethering/ homotypic fusion and vacuole protein sorting complex that is important for phagocytosis and early endosome fusion reactions. 17 Our data indicate that fibrinogen endocytosis by platelets was diminished on deletion of VPS33B, suggesting that VPS33B in required either for αIIbβ3-mediated endocytosis or subsequent trafficking of fibrinogen to α granules. Despite the lack of a detailed mechanism, the data presented here and the phenotype of the ARC syndrome patients suggest an intersection in the trafficking of de novo synthesized and endocytosed α granule cargo at a point controlled by VPS33B. This intersection also appears to contribute to integrin function in platelets. Deletion of fibrinogen affects platelet P-selectin levels. 42 Interestingly, although fibrinogen level in the VPS33B knockout platelets is much lower than that of wild-type platelets, platelet P-selectin levels in the VPS33B knockout mice are normal. It has been reported that plasma fibrinogen and the engagement of the C-terminus of fibrinogen γ chain with β3 is important for the platelet P-selectin synthesis. 42 In VPS33B knockout mice, although platelet fibrinogen is significantly reduced, plasma fibrinogen level is normal (data not shown) and the interaction between fibrinogen and platelet αIIbβ3 is not affected, because deletion of VPS33B did not affect αIIbβ3 ligand binding. However, unlike the fibrinogen knockout mice, VPS33B knockout platelets still had some fibrinogen. The small amount of fibrinogen might be sufficient for the maintenance of P-selectin in platelets.
ARC syndrome patients often experience recurrent infections. 44 Binding of VPS33B to other integrins, such as β1 integrins, could affect integrin activation in leukocytes. Therefore, our results not only establish for the first time vesicle trafficking proteins as an important novel class of modifiers of integrin function in platelets and cells but may also provide insight into the molecular mechanisms of ARC syndrome.
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SUPPLEMENTAL MATERIAL Supplemental Methods
Generation and characterization of VPS33B -/-mice
All animal experiments were approved by the Institutional Animal Care and Use
Committee of the University of Kentucky. To generate tissue-specific VPS33B knockout mice, we first generated mice harboring a "floxed" VPS33B allele and then 
Preparation of platelets
Blood was collected from the abdominal aorta of isofluorane-anesthetized mice (8) (9) (10) weeks) using 1⁄7 volume of ACD (85 mM trisodium citrate, 83 mM dextrose, and 21 mM citric acid) as anticoagulant 2 . For each experiment, blood was pooled from three to four mice of each genotype. The platelets were then washed twice with CGS (0.12 M sodium chloride, 0.0129 M trisodium citrate, 0.03 M D-glucose, pH 6.5), and resuspended in modified Tyrode's buffer (12 mM NaHCO 3 , 138 mM NaCl, 5.5 mM glucose, 2.9 mM KCl, 2 mM MgCl 2 , 0.42 mM NaH 2 PO 4 , 10 mM HEPES, pH 7.4) and incubated for 1 h at 22 °C before use.
Platelet aggregation and secretion
Platelet aggregation at 37 °C was measured by detecting changes in light transmission using a turbidimetric platelet aggregometer (Chrono-Log) with stirring (1000 rpm) 3 .
ATP release was measured by adding luciferin/luciferase reagent (3-12 µl) to 250 µl of a washed platelet suspension 1 min before stimulation.
Immunoblotting analysis of MLC phosphorylation
Polystyrene dishes (10-cm; Fisher Scientific) were precoated with 50 µg/mL fibrinogen in 0.1 M NaHCO 3 , and blocked with 5% BSA. Washed platelets (4 x 10 7 /mL, 5 mL) were either kept in suspension or added to the dishes and incubated at 37°C for various lengths of time. Dishes were washed to remove nonadherent cells.
Adherent or control platelets were directly solubilized in sample buffer containing 2% SDS, 500 mM NaCl, 50 mM Tris, pH 7.4, 5 mM ethylenediaminetetraacetic acid (EDTA), 2 mM sodium orthovanadate, 2 mM NaF, and Complete Protease Inhibitor mixture (Roche Molecular Biochemicals, Indianapolis, IN). Cell lysates were analyzed by SDS-PAGE using 4% to 15% gradient gels and immunoblotted using phospho-specific polyclonal antibodies against MLC II (Cell Signaling Technologies, Danvers, MA). Enhanced chemiluminescence (GE Healthcare, Piscataway, NJ) was used for visualization of antibody reactions. Densitometry was performed using NIH ImageJ, and integrated density of each band was measured. Quantification of each band was normalized with respect to reactivity of wild type platelets incubated on fibrinogen for 30 min for each immunoblot, and values were expressed as relative phosphorylation (mean ± SD; 3 separate experiments). Statistical significance was determined using a Student t test.
Fibrinogen binding to platelets
Washed platelets from VPS33B +/+ and VPS33B -/-mice (3 x 10 8 /ml) were incubated with Oregon Green-labeled fibrinogen in the presence of thrombin (0.025, 0.05, or 0.1 U/ml) at 22°C for various lengths of time (5, 15, or 30 min). Platelets were also incubated with Oregon Green-labeled fibrinogen in the absence of thrombin at 22°C
for 30 min as a control. Fibrinogen binding to cells was analyzed by flow cytometry.
Detection of PF4 in platelets
The total amount of PF4 in platelet lysates was measured using the anti-mouse ELISA 
Integrin expression
Washed platelets from VPS33B +/+ and VPS33B -/-mice were incubated with FITCconjugated rat anti-mouse β3 or αIIbβ3 monoclonal antibodies for 30 min at 22 °C and fixed by adding paraformaldehyde (1% final concentration). Integrin β3 or αIIbβ3 expression was analyzed by flow cytometry.
Colocalization of αIIbβ3 and VPS33B in CHO cells
CHO cells expressing αIIbβ3 (A5) were infected with an adenovirus-containing FLAG-tagged VPS33B cDNA. Two days after infection, cells were incubated in fibrinogen-coated slides for 60 min and fixed. Cells were stained with a FITC-labeled anti-FLAG monoclonal antibody and a PE-labeled anti-αIIb monoclonal antibody, and photographed using a confocal microscope. 
Platelet spreading on fibrinogen
Washed platelets (2 x 10 7 /ml) from VPS33B +/+ and VPS33B -/-mice were resuspended in Tyrode's solution. Chamber slides (Lab-Tek, Nunc, Thermo-Fisher Scientific, Rochester, NY) were coated with 50 µg/ml fibrinogen and blocked with 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS). Platelets were added to wells (100 µl/well) and allowed to spread for 30, 45, and 60 min at 37 °C 4 .
At each time point, slides were immediately rinsed to detach non-adherent platelets and fixed with 1% paraformaldehyde. Samples were blocked with 5% BSA in PBS and incubated with Rhodamine-conjugated phalloidin. Images were collected with a Leica DM IRB microscope using 60 x objective (Leica Microsystems, Wetzlar, Germany), and platelet size was quantified by using MetaMorph® microscopy automation and image analysis software. Quantification of area was normalized to wild-type platelets spreading on fibrinogen for 30 min. Statistical analysis performed using unpaired Student t test.
Platelet-mediated clot retraction
Platelet-poor plasma from healthy donors was anti-coagulated with 0.38% sodium citrate and mixed with washed platelets from VPS33B knockout mice or wild-type littermates to a concentration of 3 x 10 8 /ml 4 . Plasma was induced to coagulate with 0.4 U/ml thrombin. The clots were allowed to retract at 37°C and were photographed at various time points after addition of thrombin. Two-dimensional sizes of retracted clots on photographs were quantified using MetaMorph® microscopy automation and image analysis software, and retraction was expressed as percentage retraction (final plasma size/initial clot size). Statistical significance was determined using unpaired Student t test.
Measurement of mouse platelet serotonin
Washed platelets (5 x 10 8 /ml, 250 µl) from VPS33B +/+ and VPS33B -/-mice were solubilized by adding 60 µl of 6.0M TCA. After centrifugation at 12,000 rpm for 2 min at room temperature, the TCA extract was transferred to a tube containing 1 ml of 0.05% O-phalaldehyde. Samples were boiled for 10 min, cooled on ice, and then washed twice with chloroform. Serotonin release was measured using an MDS fluorescence spectrophotometer (MDS Analytical Technologies, Sunnyvale, CA) with an excitation wavelength of 360 nm and an emission wavelength of 475 nm.
Co-immunoprecipitation and binding assays
Human platelets or CHO cells expressing recombinant integrin αIIbβ3 were solubilized in modified RIPA Buffer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate, 1 mM NaF), or RIPA buffer (25 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) and complete protease inhibitor cocktail tablets (1 tablet/5 ml buffer, Roche). Cell lysates were incubated with 2 μg/ml of a polyclonal antibody against VPS33B, SZ21
(antibody to integrin β3), rabbit IgG, or mouse IgG, and further incubated with protein G/A-conjugated Sepharose beads or anti-FLAG M2 Affinity Gel (Sigma).
After 3-6 washes with lysis buffer, immunoprecipitates were analyzed by SDSpolyacrylamide gel electrophoresis and immunoblotting with antibodies against β3 (SZ21) or FLAG.
GST bead pull down analysis FLAG-VPS33B was purified from CHO cells infected with an adenovirus containing FLAG-VPS33B with anti-FLAG M2 Affinity Gel. Platelet lysates, lysates from CHO cells expressing FLAG-tagged VPS33B, or purified FLAG-VPS33B were incubated with glutathione beads-bound to GST, GST-αIIbCD, GST-β1CD, GST-β3CD, or various GST-β3CD truncated mutants at 4°C overnight. Bead-bound proteins were analyzed by immunoblotting. Various cDNAs of integrin-β3 cytoplasmic domains, β1CD, or αIIbCD were generated by PCR and cloned into pGEX-4T1 vector using
Bam HI and Xho I restriction sites. GST, αIIbCD, GST-β1CD, and various GSTβ3CDs were purified from BL21 (DE3) E. coli using glutathione-conjugated beads.
Cell spreading on fibrinogen or poly-L-lysine
Spreading of A5 cells infected with a null virus or an adenovirus-containing VPS33B
cDNA on fibrinogen (50 µg/ml) or poly-L-lysine. Cells were stained with Rhodamine-Phalloidin and photographed using a fluorescence microscope. Cell area was normalized to cells infected with a null virus spreading on fibrinogen (mean ± SEM). Statistical analysis performed using unpaired Student t test.
RhoA and Rac1 activity assay in platelets
Platelets adherent on immobilized fibrinogen were lysed immediately with addition of an equal volume of ice-cold lysis buffer (100 mM Tris; 400 mM NaCl; 5 mM MaCl 2 ;
2%Nonidet P-40; 20%glycerol; 2 mM PMSF; 220 Kallikrein inhibitor unit/ml aprotinin; 1mM Na 3 VO 4 ; 1 µg/ml leupeptin, pH 7.4). For A5 cells, adherent cells were lysed immediately in ice-cold lysis buffer (25 mM Tris, pH 7.4, 150 mM Nacl, 1% sodium deoxycholate, 0.1% SDS, 1% Nonidet P-40, 10 μg/ml each of aprotinin and leupeotin, 1 mM phenylmethylsulfonyl fluoride, and 200 μM sodium vanadate).
Lysates were cleared by centrifugation at 18,000 g for 2 min at 4°C, and the supernatant was incubated for 1 hour with 30 μg purified GST-Rhotekin RhoAbinding domain fusion protein (GST-RBD) bound to glutathione-Sepharose beads.
Samples were washed three times using washing buffer (50 mM Tris, pH 7.4, 10 mM 
